A detailed history of Royal Bank Of Canada transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 6,800 shares of TNGX stock, worth $20,672. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,800
Previous 6,969 2.43%
Holding current value
$20,672
Previous $59,000 11.86%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.36 - $11.93 $1,243 - $2,016
-169 Reduced 2.43%
6,800 $52,000
Q2 2024

Aug 14, 2024

BUY
$6.66 - $10.15 $29,570 - $45,066
4,440 Added 175.56%
6,969 $59,000
Q1 2024

Nov 05, 2024

SELL
$7.51 - $12.88 $33,344 - $57,187
-4,440 Reduced 63.71%
2,529 $20,000
Q1 2024

May 15, 2024

SELL
$7.51 - $12.88 $84,232 - $144,462
-11,216 Reduced 81.6%
2,529 $20,000
Q4 2023

Feb 14, 2024

BUY
$6.52 - $12.01 $40,658 - $74,894
6,236 Added 83.05%
13,745 $136,000
Q3 2023

Nov 14, 2023

BUY
$2.93 - $11.26 $8,341 - $32,057
2,847 Added 61.07%
7,509 $84,000
Q2 2023

Aug 14, 2023

BUY
$2.67 - $4.7 $5,436 - $9,569
2,036 Added 77.53%
4,662 $15,000
Q1 2023

May 15, 2023

SELL
$3.76 - $8.06 $15,179 - $32,538
-4,037 Reduced 60.59%
2,626 $10,000
Q4 2022

Feb 14, 2023

BUY
$3.41 - $8.29 $20,787 - $50,535
6,096 Added 1075.13%
6,663 $48,000
Q3 2022

Nov 14, 2022

BUY
$3.25 - $5.46 $991 - $1,665
305 Added 116.41%
567 $2,000
Q2 2022

Aug 15, 2022

SELL
$3.86 - $8.01 $15,127 - $31,391
-3,919 Reduced 93.73%
262 $1,000
Q1 2022

May 16, 2022

BUY
$7.01 - $10.94 $29,308 - $45,740
4,181 New
4,181 $32,000

Others Institutions Holding TNGX

About Tango Therapeutics, Inc.


  • Ticker TNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,067,296
  • Market Cap $268M
  • Description
  • Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...
More about TNGX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.